8-K: BioCardia Completes Enrollment in Low Dose Cohort of CardiALLO Phase I/II Trial for Ischemic Heart Failure

BioCardia announces the completion of enrollment and dosing in the low dose cohort of its CardiALLO Phase I/II trial, evaluating allogeneic mesenchymal stem cells for treating ischemic heart failure.

Summary

• BioCardia, Inc. has completed enrollment and dosing in the low dose cohort of its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial.
• The trial is designed to treat patients with ischemic heart failure of reduced ejection fraction (HFrEF).
• This trial is believed to be the world's first prospective trial of allogeneic mesenchymal stem cells (MSC) intended for treating HFrEF patients with elevated markers of heart stress and systemic inflammation.
• The Phase I portion of the trial involves a nine-patient dose escalation cohort, with three patients receiving one of three escalating doses: 20 million, 100 million, and 200 million cells.
• The treatment uses BioCardia's minimally invasive delivery system.
• A two-week waiting period between each dose cohort is included, with a formal Data Safety Monitoring Board (DSMB) review following each dose.
• The first DSMB review is expected in March 2025.
• The company is utilizing the Morph DNA guide to navigate, enhancing physician control for cell delivery.
• The program follows two previous clinical trials of allogeneic MSC delivered intramyocardially for patients with ischemic heart failure sponsored by BioCardia.
• The company intends to position this therapy for pivotal clinical studies in the United States and conditional time limited approval in Japan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of a trial milestone and the potential of the therapy. However, the presence of forward-looking statements and associated risks tempers the overall optimism.

Positives

• The completion of enrollment and dosing in the low dose cohort is a positive milestone for the CardiALLO trial.
• The use of allogeneic MSCs offers a potential 'off-the-shelf' treatment option.
• The Morph DNA guide enhances physician control for cell delivery, potentially improving treatment precision.
• Previous trials have shown evidence for safety and trends of efficacy for these allogeneic cells.
• The company's enhanced manufacturing of MSC is expected to be commercially scalable.
• A first MSC therapy was recently approved in the United States.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• The company's liquidity position and its ability to raise additional funds could impact the progress of clinical trials.
• The company's ability to successfully progress its clinical trials is not guaranteed.
• Future regulatory approvals are not guaranteed.

Future Outlook

The company anticipates future enrollment in its ongoing clinical trial, potential regulatory approvals, and the ultimate success of its clinical cell therapy programs. They also intend to position this therapy for pivotal clinical studies in the United States and conditional time limited approval in Japan.

Management Comments

• Carl Pepine, M.D., stated that the novel investigational cell therapy has great potential to help patients with significant lifestyle limitations.
• R. David Anderson, M.D., noted that the treatment procedures have gone well and expressed anticipation for the first independent safety review.
• Peter Altman, PhD, expressed confidence in the CardiALLO MSC program and its potential for pivotal clinical studies and conditional approval in Japan.

Industry Context

The announcement highlights the growing interest in cell-based therapies for cardiovascular diseases. The recent approval of a first MSC therapy in the United States underscores the increasing regulatory acceptance of these treatments. BioCardia's focus on allogeneic MSCs aligns with the industry's pursuit of 'off-the-shelf' solutions that can be readily available to patients.

Comparison to Industry Standards

• The press release references two previous clinical trials of allogeneic MSC delivered intramyocardially for patients with ischemic heart failure sponsored by BioCardia, suggesting a history of research in this area.
• The company's CardiALLO program is intended to position this therapy for pivotal clinical studies in the United States and conditional time limited approval in Japan, similar to Helios's application for ARDS in Japan.
• The company mentions a first MSC therapy was recently approved in the United States, indicating a benchmark for regulatory approval in the cell therapy space.

Stakeholder Impact

• Shareholders may react positively to the progress in the CardiALLO trial.
• Patients with ischemic heart failure may benefit from the potential new treatment option.
• The company's employees are involved in the development and manufacturing of the cell therapy.
• Potential partners may be interested in the PulmAllo MSC acute respiratory distress IND.

Next Steps

• The first DSMB review is expected to take place in March 2025.
• The company intends to continue enrollment in the Phase I/II trial.
• BioCardia aims to position the CardiALLO therapy for pivotal clinical studies in the United States and conditional time-limited approval in Japan.

Key Dates

Keywords

CardiALLO, BioCardia, ischemic heart failure, allogeneic mesenchymal stem cells, HFrEF, MSC, clinical trial, cell therapy